Mitral Valve

The heart's mitral valve is the site of the most surgical valve repairs and valve replacements. After the resounding success of transcatheter aortic valve replacement (TAVR), which now makes up more than 50% of aortic valve replacements, there is wide expectation transcatheter mitral replacements will follow in the next few year. Currently, the most common transcatheter mitral procedure is transcatheter edge-to-edge (TEER) , using the MitraClip or Pascal clip devices. These devices are also being used for transcatheter tricuspid valve repair (TTVR). Other transcatheter mitral repair systems are in trials for minimally invasive annuloplasty and chordae tendineae repair. 

RSS icon
Edwards Lifesciences Sapien 3 transcatheter heart valve used for Mitral Valve-in-Valve

Transcatheter mitral valve-in-valve replacement benefits intermediate-risk patients

New one-year data suggests transseptal MViV with a Sapien 3 heart valve is a "favorable and safe procedure." Researchers plan to follow patients for a total of 10 years.

Innovalve Bio Medical's Innostay TMVR device. Edwards Lifesciences has agreed to acquire Innovalve after an initial investment in 2017.

Edwards Lifesciences to acquire medical device startup behind new TMVR technology

Edwards, an early investor when the company first launched in 2017, said the acquisition will ensure its TMVR platform reaches as many patients as possible. 

dollar money graph increase finance

Market for transcatheter heart valve replacement could top $19B in 10 years

As one may expect, advances in TAVR and TMVR technologies are seen as key drivers of the market’s success.

The Tria surgical mitral valve is built using LifePolymer, a proprietary material that does not include animal tissue. Both the frame of the valve and its leaflets are generated by computer to match each patient’s native mitral valve. According to Foldax, this new-look polymer reduces the long-term risk of valve calcification, and patients should be able to bounce back after surgery without requiring the long-time use of anticoagulants.

New-look polymer mitral valve linked to positive outcomes 30 days after surgery

The new surgical valve from Foldax was designed to limit calcification and make it so patients do not require long-term anticoagulant therapy following treatment. 

M&A mergers and acquisitions business deal

Edwards Lifesciences sells critical care business to BD for $4.2B—remains ‘laser focused’ on structural heart disease

This move represents a pivot of sorts for Edwards; instead of pursuing a spin-off of its critical care business, the company is now doubling down on its commitment to develop new structural heart technologies. BD, meanwhile, says the transaction will deliver significant value. 

Transcatheter mitral valve interventions linked to lower stroke risk than surgery

Researchers performed a new meta-analysis of data from more than 51,000 patients. They examined a wide range of outcomes that also included AFib and all-cause mortality.

Newsweek ranked the 50 best heart hospitals in the world

New York Valves, CRF’s newest cardiology conference, makes heart team collaborations a priority

New York Valves: The Structural Heart Summit replaces the Transcatheter Valve Therapy conference CRF hosted for many years. The three-day event will include 12 late-breaking clinical trials focused on TAVR and new treatments for the mitral and tricuspid valves. 

4C Medical Technologies AltaValve

FDA grants breakthrough device designation to new TMVR device from 4C Medical

The supra-annular AltaValve System was designed to treat both primary and secondary mitral regurgitation. It is implanted via transseptal access and positioned above the native mitral valve.

Displaying 9 - 16 of 105
Design by Adaptive Theme